CA2167410A1 - Endothelin antagonists - Google Patents

Endothelin antagonists

Info

Publication number
CA2167410A1
CA2167410A1 CA002167410A CA2167410A CA2167410A1 CA 2167410 A1 CA2167410 A1 CA 2167410A1 CA 002167410 A CA002167410 A CA 002167410A CA 2167410 A CA2167410 A CA 2167410A CA 2167410 A1 CA2167410 A1 CA 2167410A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
unsubstituted
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002167410A
Other languages
English (en)
French (fr)
Inventor
William J. Greenlee
Thomas F. Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2167410A1 publication Critical patent/CA2167410A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002167410A 1993-07-20 1994-07-15 Endothelin antagonists Abandoned CA2167410A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9512693A 1993-07-20 1993-07-20
US095,126 1993-07-20
US267,981 1994-07-07
US08/267,981 US5686478A (en) 1993-07-20 1994-07-07 Endothelin antagonists

Publications (1)

Publication Number Publication Date
CA2167410A1 true CA2167410A1 (en) 1995-02-02

Family

ID=26789812

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002167410A Abandoned CA2167410A1 (en) 1993-07-20 1994-07-15 Endothelin antagonists

Country Status (6)

Country Link
US (1) US5686478A (show.php)
EP (1) EP0710235A1 (show.php)
JP (1) JPH09500644A (show.php)
AU (1) AU683677B2 (show.php)
CA (1) CA2167410A1 (show.php)
WO (1) WO1995003295A1 (show.php)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030358A1 (en) * 1995-03-27 1996-10-03 Smithkline Beecham Plc Phenyl derivatives useful as endothelin receptor antagonists
DE19533025A1 (de) * 1995-09-07 1997-03-13 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
AU7447500A (en) * 1999-09-30 2001-04-30 Mitsubishi Chemical Corporation Acylsulfonamide derivatives
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
KR100784958B1 (ko) * 2000-02-04 2007-12-11 테라코스, 인코포레이티드 신규한 디페닐에틸렌 화합물
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
ATE417503T1 (de) * 2000-02-04 2009-01-15 Theracos Inc Neue diphenylethylene-verbindungen
AU2001254555A1 (en) 2000-04-24 2001-11-07 Merck Frosst Canada & Co Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
AU2001278709A1 (en) 2000-08-11 2002-02-25 Kaken Pharmaceutical Co..Ltd. 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
WO2016009322A1 (en) * 2014-07-15 2016-01-21 Sifavitor S.R.L. Amorphous form and new crystalline forms of macitentan

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1408738A (fr) * 1964-04-29 1965-08-20 Nobel Bozel Nouveaux dérivés de l'acide bis(hydroxy-4-phényl)-acétique
US4268512A (en) * 1976-08-04 1981-05-19 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
DE3829431A1 (de) * 1988-08-31 1990-03-01 Boehringer Mannheim Gmbh Sulfonamide mit tetrazolylrest, verfahren zur ihrer herstellung sowie arzneimittel
US5082838A (en) * 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
JPH0347163A (ja) * 1989-06-30 1991-02-28 Fujisawa Pharmaceut Co Ltd アントラキノン誘導体およびその製造
CA2032559C (en) * 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
IE75693B1 (en) * 1990-07-10 1997-09-10 Janssen Pharmaceutica Nv HIV-inhibiting benzeneacetamide derivatives
CA2059380A1 (en) * 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
DK0526642T3 (da) * 1991-01-29 1998-10-19 Shionogi & Co Triterpenderivat
EP0574530A4 (en) * 1991-03-08 1996-04-03 Res Corp Technologies Inc Endothelin antagonists
TW270116B (show.php) * 1991-04-25 1996-02-11 Hoffmann La Roche
DE69231404T2 (de) * 1991-05-16 2001-02-08 Warner-Lambert Co., Ann Arbor Endothelinantagonisten
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
GB9112681D0 (en) * 1991-06-13 1991-07-31 Mecanex Limited Window/ventilator structure
SK282098B6 (sk) * 1991-11-05 2001-11-06 Smithkline Beecham Corporation Indánové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
EP0620809B1 (en) * 1991-12-30 1997-03-05 Janssen Pharmaceutica N.V. $g(a)-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES
PH30258A (en) * 1991-12-30 1997-02-05 Janssen Pharmaceutica Nv Heterocycle-substituted benzenemethanamine derivatives
TW224462B (show.php) * 1992-02-24 1994-06-01 Squibb & Sons Inc
WO1993017681A1 (en) * 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
AU4376893A (en) * 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
US5559105A (en) * 1992-07-17 1996-09-24 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1994002474A1 (en) * 1992-07-17 1994-02-03 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH06122625A (ja) * 1992-10-12 1994-05-06 Asahi Chem Ind Co Ltd エンドセリン受容体拮抗剤
TW287160B (show.php) * 1992-12-10 1996-10-01 Hoffmann La Roche
WO1994014796A1 (fr) * 1992-12-21 1994-07-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de n-(pyridylcarbonyl)benzazepine et son intermediaire
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US5352800A (en) * 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
DK0617001T3 (da) * 1993-03-19 2000-04-17 Merck & Co Inc Phenoxyphenyleddikesyrederivater
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives

Also Published As

Publication number Publication date
JPH09500644A (ja) 1997-01-21
EP0710235A4 (show.php) 1996-06-12
EP0710235A1 (en) 1996-05-08
AU683677B2 (en) 1997-11-20
WO1995003295A1 (en) 1995-02-02
AU7257194A (en) 1995-02-20
US5686478A (en) 1997-11-11

Similar Documents

Publication Publication Date Title
DE69422742T2 (de) Phenoxyphenylessigsäurederivate
US5668176A (en) Phenoxyphenylacetic acid derivatives
CA2167410A1 (en) Endothelin antagonists
WO1995003044A1 (en) Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US5538991A (en) Endothelin antagonists bearing 5-membered heterocyclic amides
WO1996009818A1 (en) Endothelin receptor antagonists for the treatment of emesis
US5559135A (en) Endothelin antagonists bearing pyridyl amides
US5334598A (en) Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
IL228677A (en) Branched and used 3-phenylpropionic acid history
US5401745A (en) Quinazolinones substituted with phenoxyphenylacetic acid derivatives
GB2277446A (en) Quinazolinones useful as endothelin antagonists
EP0774965A1 (en) Phenoxyphenylacetic acid derivatives
PL174431B1 (pl) Nowe kwasy benzenoalkanoilowe lub pochodne nowych kwasów benzenoalkanoilowych
US5767310A (en) Phenoxyphenylacetic acid derivatives
US5492917A (en) Endothelin antagonists incorporating a cyclobutane
AU705881B2 (en) Phenoxyphenylacetic acid derivatives
CA2308478C (en) Indole derivatives useful as endothelin receptor antagonist
US12458624B2 (en) Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides
Baccus et al. Synthesis of fatty acid binding protein inhibitors: a new approach for diabetes treatment
JP2008303177A (ja) Ｐａｉ−１産生抑制作用を有する５−アルキル−５−フェニル−３−ピリダジノン誘導体

Legal Events

Date Code Title Description
FZDE Discontinued